Instil Bio Partners with ImmuneOnco for Cancer Therapy

Instil Bio ( (TIL) ) has provided an update.

Instil Bio has announced its collaboration with ImmuneOnco Biopharmaceuticals to advance the clinical development of AXN-2510, a PD-L1xVEGF bispecific antibody, with a focus on non-small cell lung cancer (NSCLC). The collaboration aims to leverage rapid patient enrollment in China and potentially expedite regulatory strategies, positioning Instil Bio to compete in the substantial oncology market projected to grow significantly by 2028.

The most recent analyst rating on (TIL) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Instil Bio stock, see the TIL Stock Forecast page.

Spark’s Take on TIL Stock

According to Spark, TipRanks’ AI Analyst, TIL is a Underperform.

Instil Bio’s stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.

To see Spark’s full report on TIL stock, click here.

More about Instil Bio

Instil Bio, Inc. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is particularly involved in creating bispecific antibodies targeting PD-L1 and VEGF pathways, which are significant in oncology treatment.

Average Trading Volume: 125,746

Technical Sentiment Signal: Sell

Current Market Cap: $107.8M

Find detailed analytics on TIL stock on TipRanks’ Stock Analysis page.